Lack of response to octreotide in Cushing's syndrome due to metastatic adrenocortical carcinoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 10448470.
- Also identified by PMC identifier 1741126.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Functional metastatic adrenocortical carcinoma is an uncommon cause of Cushing's syndrome, which rarely responds to conventional treatment. A patient presenting with Cushing's syndrome secondary to adrenocortical carcinoma underwent surgical resection. Postoperatively, she developed metastatic disease resistant to conventional chemotherapy. Octreotide, a somatostatin analogue which is effective in the treatment of several types of neuroendocrine tumour, was tried to ameliorate her secretory symptoms, but without any therapeutic effect.
Medical subject headings
- Adrenocortical Carcinoma
- Cushing Syndrome
- Hormones
- Octreotide